MA54653A - Modulateurs du récepteur de cxcr7 pipéridine - Google Patents

Modulateurs du récepteur de cxcr7 pipéridine

Info

Publication number: MA54653A
Authority: MA; Morocco
Prior art keywords: cxcr7; piperidine; receptor modulators; modulators; receptor
Prior art date: 2016-07-28

Application number

MA054653A

Other languages

English (en)

Other versions

MA54653B1 (fr

Inventor

Hamed Aissaoui

Philippe Guerry

Francois Lehembre

Julien Pothier

Laetitia Pouzol

Sylvia Richard-Bildstein

Shuguang Yuan

Original Assignee

Idorsia Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-07-28

Filing date

2017-07-27

Publication date

2021-12-29

2017-07-27 Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd

2021-12-29 Publication of MA54653A publication Critical patent/MA54653A/fr

2023-04-28 Publication of MA54653B1 publication Critical patent/MA54653B1/fr

Links

102100022716 Atypical chemokine receptor 3 Human genes 0.000 title 1
101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 title 1
102000005962 receptors Human genes 0.000 title 1
108020003175 receptors Proteins 0.000 title 1
NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

MA54653A 2016-07-28 2017-07-27 Modulateurs du récepteur de cxcr7 pipéridine MA54653B1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP2016068052		2016-07-28

Publications (2)

Publication Number	Publication Date
MA54653A true MA54653A (fr)	2021-12-29
MA54653B1 MA54653B1 (fr)	2023-04-28

Family

ID=59656027

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA54653A MA54653B1 (fr)	2016-07-28	2017-07-27	Modulateurs du récepteur de cxcr7 pipéridine
MA45782A MA45782B1 (fr)	2016-07-28	2017-07-27	Modulateurs du récepteur de cxcr7 pipéridine

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MA45782A MA45782B1 (fr)	2016-07-28	2017-07-27	Modulateurs du récepteur de cxcr7 pipéridine

Country Status (32)

Country	Link
US (2)	US10752620B2 (fr)
EP (2)	EP3490986B1 (fr)
JP (2)	JP6655754B2 (fr)
KR (2)	KR102497095B1 (fr)
CN (2)	CN110563717B (fr)
AR (2)	AR109180A1 (fr)
AU (2)	AU2017302079B2 (fr)
CA (1)	CA3032017C (fr)
CL (2)	CL2019000169A1 (fr)
CY (1)	CY1125016T1 (fr)
DK (2)	DK3490986T3 (fr)
EA (2)	EA037507B1 (fr)
ES (2)	ES2954152T3 (fr)
FI (1)	FI3798217T3 (fr)
HR (2)	HRP20230313T1 (fr)
HU (2)	HUE057315T2 (fr)
IL (2)	IL264424B (fr)
LT (2)	LT3490986T (fr)
MA (2)	MA54653B1 (fr)
MX (2)	MX383804B (fr)
MY (2)	MY198113A (fr)
NZ (1)	NZ751006A (fr)
PH (2)	PH12021552605A1 (fr)
PL (2)	PL3798217T3 (fr)
PT (2)	PT3798217T (fr)
RS (2)	RS64130B1 (fr)
SG (2)	SG11201900633XA (fr)
SI (2)	SI3490986T1 (fr)
TW (3)	TWI691494B (fr)
UA (2)	UA122987C2 (fr)
WO (1)	WO2018019929A1 (fr)
ZA (1)	ZA201901256B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102502046B1 (ko) *	2018-01-26	2023-02-20	이도르시아 파마슈티컬스 리미티드	Cxcr7 수용체 작동제 (3s,4s)-1-시클로프로필메틸-4-｛[5-(2,4-디플루오로-페닐)-이속사졸-3-카르보닐]-아미노｝-피페리딘-3-카르복실산 (1-피리미딘-2-일-시클로프로필)-아미드의 결정질 형태
CA3156298A1 (fr) *	2019-10-31	2021-05-06	Laetitia POUZOL	Combinaison d'un antagoniste de cxcr7 avec un modulateur du recepteur s1p1
WO2022136486A1 (fr) *	2020-12-22	2022-06-30	Luxembourg Institute Of Health (Lih)	Analogues de la conolidine servant de modulateurs sélectifs d'ackr3 pour traiter le cancer
EP4326257A4 (fr) *	2021-04-19	2025-03-12	ChemoCentryx, Inc.	Azétidinyl-acétamides utilisés comme inhibiteurs de cxcr7
EP4717089A3 (fr)	2021-08-02	2026-06-24	Syngenta Crop Protection AG	Derives de pyrazole microbiocides
MX2023013961A (es)	2021-10-01	2023-12-11	Nextgen Bioscience Co Ltd	Nuevos derivados de la piperidina y composiciones farmaceuticas que los contienen, para inhibir la autotaxina.
EP4447682A1 (fr)	2021-12-17	2024-10-23	Syngenta Crop Protection AG	Dérivés de pyrazole microbiocides
EP4238970A1 (fr) *	2022-03-03	2023-09-06	InterAx Biotech AG	Modulateurs de ackr3 et leurs utilisations
CN115403510B (zh) *	2022-08-11	2023-04-25	南方医科大学	一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途
TW202434579A (zh)	2022-11-16	2024-09-01	瑞士商先正達農作物保護股份公司	殺微生物的四氫異喹啉衍生物
TW202439972A (zh)	2022-11-30	2024-10-16	瑞士商先正達農作物保護股份公司	殺真菌組成物
JP2025539452A (ja)	2022-11-30	2025-12-05	シンジェンタクロッププロテクションアクチェンゲゼルシャフト	殺微生物テトラヒドロイソキノリン誘導体
PY2403614A (es)	2023-01-27	2025-09-11	Syngenta Crop Protection Ag	Derivados de pirazol microbiocidas
PY2404467A (es)	2023-02-01	2025-03-31	Syngenta Crop Protection Ag	Composiciones fungicidas
PY2447478A (es)	2023-06-14	2025-03-18	Syngenta Crop Protection Ag	Composiciones fungicidas
AR135142A1 (es)	2024-01-03	2026-07-08	Pi Industries Ltd	Amidas heterocíclicas bicíclicas para combatir hongos fitopatógenos
AR135141A1 (es)	2024-01-03	2026-07-08	Pi Industries Ltd	Compuestos de pirazol para combatir hongos fitopatógenos
AR134999A1 (es)	2024-02-02	2026-05-20	Syngenta Crop Protection Ag	Derivados de pirazol microbiocidas
WO2025172368A1 (fr)	2024-02-13	2025-08-21	Syngenta Crop Protection Ag	Dérivés de (5-isoxazol-3-yl)-[4-(pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]méthanone destinés à être utilisés en tant que fongicides
WO2026030052A1 (fr)	2024-07-31	2026-02-05	Fmc Corporation	Azoles substitués fongicides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040102324A1 (en) *	2002-02-28	2004-05-27	Annis Gary David	Heterocyclic diamide invertebrate pest control agents
WO2004050024A2 (fr)	2002-11-27	2004-06-17	Incyte Corporation	Derives de la 3-aminopyrrolidine modulateurs des recepteurs de la chemoquine
TW200526626A (en) *	2003-09-13	2005-08-16	Astrazeneca Ab	Chemical compounds
US7115646B2 (en)	2003-10-08	2006-10-03	Bristol Myers Squibb, Co.	Cyclic diamines and derivatives as factor Xa inhibitors
ES2430569T3 (es) *	2005-02-18	2013-11-21	Astrazeneca Ab	Compuestos antibacterianos derivados de piperidina
KR101701367B1 (ko) *	2008-11-04	2017-02-02	케모센트릭스, 인크.	Ｃｘｃｒ７의 모듈레이터
US8921398B2 (en)	2011-06-09	2014-12-30	Boehringer Ingelheim International Gmbh	N-cyclopropyl-N-piperidinyl-amide derivatives, pharmaceutical compositions and uses thereof
WO2013084241A1 (fr) *	2011-12-09	2013-06-13	Cadila Healthcare Limited	Composés inhibiteurs de rénine
AR091516A1 (es)	2012-06-22	2015-02-11	Actelion Pharmaceuticals Ltd	Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
AU2013352304C1 (en) *	2012-11-29	2018-03-22	Chemocentryx, Inc.	CXCR7 antagonists
BR112015030095B1 (pt)	2013-05-30	2023-02-28	Idorsia Pharmaceuticals Ltd	Moduladores do receptor de cxcr7
MX2016002544A (es)	2013-09-04	2016-06-17	Squibb Bristol Myers Co	Compuestos utiles como inmunomoduladores.
RS57508B1 (sr)	2013-09-06	2018-10-31	Aurigene Discovery Tech Ltd	1,2,4-derivati oksadiazola kao imunomodulatori
WO2015044900A1 (fr)	2013-09-27	2015-04-02	Aurigene Discovery Technologies Limited	Composés immunomodulateurs thérapeutiques
BR112017004589A2 (pt)	2014-09-10	2018-01-23	Epizyme Inc	composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
US10202368B2 (en)	2014-12-01	2019-02-12	Idorsia Pharmaceuticals Ltd.	CXCR7 receptor modulators
KR102502046B1 (ko)	2018-01-26	2023-02-20	이도르시아 파마슈티컬스 리미티드	Cxcr7 수용체 작동제 (3s,4s)-1-시클로프로필메틸-4-｛[5-(2,4-디플루오로-페닐)-이속사졸-3-카르보닐]-아미노｝-피페리딘-3-카르복실산 (1-피리미딘-2-일-시클로프로필)-아미드의 결정질 형태

2017
- 2017-07-27 EP EP17754283.4A patent/EP3490986B1/fr active Active
- 2017-07-27 US US16/320,906 patent/US10752620B2/en active Active
- 2017-07-27 LT LTEPPCT/EP2017/068990T patent/LT3490986T/lt unknown
- 2017-07-27 SG SG11201900633XA patent/SG11201900633XA/en unknown
- 2017-07-27 KR KR1020207021496A patent/KR102497095B1/ko active Active
- 2017-07-27 HU HUE17754283A patent/HUE057315T2/hu unknown
- 2017-07-27 ES ES20201796T patent/ES2954152T3/es active Active
- 2017-07-27 KR KR1020197005980A patent/KR102497091B1/ko active Active
- 2017-07-27 PT PT202017968T patent/PT3798217T/pt unknown
- 2017-07-27 RS RS20230297A patent/RS64130B1/sr unknown
- 2017-07-27 AU AU2017302079A patent/AU2017302079B2/en active Active
- 2017-07-27 TW TW108111236A patent/TWI691494B/zh active
- 2017-07-27 DK DK17754283.4T patent/DK3490986T3/da active
- 2017-07-27 AR ARP170102126A patent/AR109180A1/es active IP Right Grant
- 2017-07-27 UA UAA201901844A patent/UA122987C2/uk unknown
- 2017-07-27 MY MYPI2019000420A patent/MY198113A/en unknown
- 2017-07-27 EA EA201990388A patent/EA037507B1/ru not_active IP Right Cessation
- 2017-07-27 TW TW108111240A patent/TWI691497B/zh active
- 2017-07-27 HR HRP20230313TT patent/HRP20230313T1/hr unknown
- 2017-07-27 PH PH1/2021/552605A patent/PH12021552605A1/en unknown
- 2017-07-27 LT LTEP20201796.8T patent/LT3798217T/lt unknown
- 2017-07-27 FI FIEP20201796.8T patent/FI3798217T3/fi active
- 2017-07-27 ES ES17754283T patent/ES2905755T3/es active Active
- 2017-07-27 SI SI201731053T patent/SI3490986T1/sl unknown
- 2017-07-27 CN CN201910748606.6A patent/CN110563717B/zh active Active
- 2017-07-27 NZ NZ751006A patent/NZ751006A/en unknown
- 2017-07-27 JP JP2019503918A patent/JP6655754B2/ja active Active
- 2017-07-27 DK DK20201796.8T patent/DK3798217T3/da active
- 2017-07-27 HR HRP20211988TT patent/HRP20211988T1/hr unknown
- 2017-07-27 SI SI201731333T patent/SI3798217T1/sl unknown
- 2017-07-27 PL PL20201796.8T patent/PL3798217T3/pl unknown
- 2017-07-27 TW TW106125273A patent/TWI683812B/zh active
- 2017-07-27 MY MYPI2021006484A patent/MY199657A/en unknown
- 2017-07-27 RS RS20220082A patent/RS62855B1/sr unknown
- 2017-07-27 EP EP20201796.8A patent/EP3798217B1/fr active Active
- 2017-07-27 WO PCT/EP2017/068990 patent/WO2018019929A1/fr not_active Ceased
- 2017-07-27 MX MX2019001042A patent/MX383804B/es unknown
- 2017-07-27 PL PL17754283T patent/PL3490986T3/pl unknown
- 2017-07-27 CN CN201780046279.9A patent/CN109563085B/zh active Active
- 2017-07-27 MA MA54653A patent/MA54653B1/fr unknown
- 2017-07-27 PT PT177542834T patent/PT3490986T/pt unknown
- 2017-07-27 MA MA45782A patent/MA45782B1/fr unknown
- 2017-07-27 EA EA202091262A patent/EA202091262A1/ru unknown
- 2017-07-27 CA CA3032017A patent/CA3032017C/fr active Active
- 2017-07-27 HU HUE20201796A patent/HUE062019T2/hu unknown
- 2017-07-27 UA UAA202002568A patent/UA129887C2/uk unknown
- 2017-07-27 SG SG10201906942PA patent/SG10201906942PA/en unknown
2019
- 2019-01-22 CL CL2019000169A patent/CL2019000169A1/es unknown
- 2019-01-23 IL IL264424A patent/IL264424B/en unknown
- 2019-01-24 MX MX2021004000A patent/MX2021004000A/es unknown
- 2019-01-25 PH PH12019500188A patent/PH12019500188A1/en unknown
- 2019-02-27 ZA ZA2019/01256A patent/ZA201901256B/en unknown
- 2019-03-15 JP JP2019048980A patent/JP6655742B2/ja active Active
- 2019-07-01 AR ARP190101842A patent/AR115662A2/es active IP Right Grant
- 2019-11-15 CL CL2019003281A patent/CL2019003281A1/es unknown
2020
- 2020-07-09 AU AU2020204578A patent/AU2020204578B2/en active Active
- 2020-07-14 US US16/928,787 patent/US11306078B2/en active Active
2021
- 2021-05-05 IL IL282942A patent/IL282942B/en unknown
2022
- 2022-02-21 CY CY20221100143T patent/CY1125016T1/el unknown

Also Published As

Publication number	Publication date
PL3490986T3 (pl)	2022-04-04
CA3032017C (fr)	2023-04-18
CN109563085B (zh)	2022-08-09
JP6655742B2 (ja)	2020-02-26
EP3490986B1 (fr)	2021-11-24
HRP20230313T1 (hr)	2023-05-12
LT3798217T (lt)	2023-05-25
EA037507B1 (ru)	2021-04-06
MX2019001042A (es)	2019-06-10
US10752620B2 (en)	2020-08-25
CN110563717A (zh)	2019-12-13
CL2019003281A1 (es)	2020-05-04
CL2019000169A1 (es)	2019-06-21
UA129887C2 (uk)	2025-09-03
NZ755815A (en)	2025-02-28
SI3490986T1 (sl)	2022-02-28
TW201922738A (zh)	2019-06-16
JP2019525927A (ja)	2019-09-12
TWI683812B (zh)	2020-02-01
AU2020204578B2 (en)	2022-03-10
EP3798217A1 (fr)	2021-03-31
US20200385373A1 (en)	2020-12-10
AU2017302079B2 (en)	2021-07-22
BR112019001551A2 (pt)	2019-05-14
PH12021552605A1 (en)	2023-01-23
IL282942B (en)	2022-01-01
TW201932454A (zh)	2019-08-16
UA122987C2 (uk)	2021-01-27
CA3032017A1 (fr)	2018-02-01
KR20200092420A (ko)	2020-08-03
TW201806940A (zh)	2018-03-01
JP2019142874A (ja)	2019-08-29
ES2905755T3 (es)	2022-04-12
MX2021004000A (es)	2021-06-23
SG10201906942PA (en)	2019-09-27
IL264424B (en)	2021-08-31
MY199657A (en)	2023-11-14
JP6655754B2 (ja)	2020-02-26
PT3798217T (pt)	2023-05-23
AU2020204578A1 (en)	2020-07-30
MY198113A (en)	2023-08-03
EP3490986A1 (fr)	2019-06-05
KR102497091B1 (ko)	2023-02-06
AU2017302079A1 (en)	2019-03-21
EP3798217B1 (fr)	2023-02-22
PH12019500188A1 (en)	2019-10-21
CN109563085A (zh)	2019-04-02
FI3798217T3 (fi)	2023-05-03
IL282942A (en)	2021-06-30
HRP20211988T1 (hr)	2022-03-18
ES2954152T3 (es)	2023-11-20
CY1125016T1 (el)	2023-03-24
MA45782A (fr)	2019-06-05
HUE062019T2 (hu)	2023-09-28
KR102497095B1 (ko)	2023-02-06
WO2018019929A1 (fr)	2018-02-01
MA45782B1 (fr)	2021-12-31
US20190169180A1 (en)	2019-06-06
SI3798217T1 (sl)	2023-05-31
RS64130B1 (sr)	2023-05-31
EA201990388A1 (ru)	2019-08-30
MA54653B1 (fr)	2023-04-28
SG11201900633XA (en)	2019-02-27
AR109180A1 (es)	2018-11-07
MX383804B (es)	2025-03-14
TWI691494B (zh)	2020-04-21
EA202091262A1 (ru)	2020-08-13
KR20190034620A (ko)	2019-04-02
AR115662A2 (es)	2021-02-10
LT3490986T (lt)	2022-02-10
PL3798217T3 (pl)	2023-06-12
DK3798217T3 (da)	2023-05-22
HUE057315T2 (hu)	2022-04-28
TWI691497B (zh)	2020-04-21
ZA201901256B (en)	2021-08-25
CN110563717B (zh)	2022-08-09
RS62855B1 (sr)	2022-02-28
US11306078B2 (en)	2022-04-19
DK3490986T3 (da)	2022-03-07
IL264424A (en)	2019-02-28
NZ751006A (en)	2021-07-30
PT3490986T (pt)	2022-02-01

Publication	Publication Date	Title
IL282942B (en)	2022-01-01	Piperidine cxcr7 receptor modulators
MA43382A (fr)	2018-10-10	Modulateurs des récepteurs des chimiokines
EP3442971A4 (fr)	2020-01-01	Modulateurs du récepteur des estrogènes
PT3494133T (pt)	2022-09-28	Recetores de células t anti-kras-g12d
EP3521427A4 (fr)	2020-04-22	Co-récepteur de récepteur odorant
DK3359160T3 (da)	2021-11-22	Farnesoid x receptor modulatorer
PL3274366T3 (pl)	2020-06-15	Chimeryczny receptor antygenowy
MA55328A (fr)	2022-01-19	Modulateurs de ror-gamma
PT3223850T (pt)	2020-04-13	Receptores de células t anti-kras mutado
MA53943A (fr)	2021-08-25	Modulateurs de ror-gamma
PT3101032T (pt)	2019-04-03	Onjugado de anticorpo anti-her2-fármaco
MA42133A (fr)	2021-06-02	Modulateurs du ccr2
EP3219592C0 (fr)	2024-08-21	Fixation
EP3286210C0 (fr)	2023-10-18	Récepteur de lymphocyte t
EP3565543A4 (fr)	2020-10-14	Modulateurs du récepteur opioïde de type mu
MA52555A (fr)	2021-03-17	Modulateurs du récepteur des oestrogènes
EP3529267C0 (fr)	2023-07-26	Récepteur de lymphocytes t
IL247140B (en)	2020-02-27	Pyrazines modulators of gpr6
DK3819287T3 (da)	2023-12-18	Amorft tapentadolphosphat
EP3532062A4 (fr)	2020-04-15	Modulateurs de ror-gamma
EP3408286C0 (fr)	2024-11-06	Protéines g
EP3421454A4 (fr)	2019-08-14	Dérivé de pipéridine
DK3126521T3 (da)	2019-06-17	HNF4G-RSPO2-fusionsgen
PT3302948T (pt)	2020-07-02	Unidade de força de fecho
FR3018292B1 (fr)	2016-03-25	Module de construction du type gabion